Contineum Therapeutics, Inc. (CTNM) Misses Q2 EPS by 34c
Tweet
Share
E-mailGet Alerts CTNM Hot Sheet
Join SI Premium – FREE
Contineum Therapeutics, Inc. (NASDAQ: CTNM) reported Q2 EPS of ($0.62), $0.34 worse than the analyst estimate of ($0.28).
For earnings history and earnings-related data on Contineum Therapeutics, Inc. (CTNM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- NIO Inc. (NIO) Tops Q2 EPS by 33c; offers guidance
- Credo Technology Group Holding (CRDO) Tops Q1 EPS by 4c; offers guidance
- Albany International ends strategic review, keeps Salt Lake City facility
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
